International real-world study of DLL3 expression in patients with small cell lung cancer

Federico Rojo , Marcelo Corassa , Dimitrios Mavroudis , Aysim Büge Öz , Bonne Biesma , Luka Brcic , Patrick Pauwels , Verena Sailer , John Gosney , Darko Miljkovic , Carlos Hader , Meijing Wu , Todd Almarez , Frédérique Penault-Llorca (1, 2)

1 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
2 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]

Expression of the Notch-family ligand delta-like protein 3 (DLL3), a potential therapeutic target in small cell lung cancer (SCLC), has not been assessed in the real-world setting. To identify the real-world utility of DLL3 as an SCLC therapeutic target, we performed the largest retrospective international noninterventional study to date to evaluate DLL3 prevalence in SCLC patients.

Mots clés: Biomarker; DLL3; Real-world analysis; Small cell lung cancer

Domaines: Sciences du Vivant [q-bio]

Federico Rojo, Marcelo Corassa, Dimitrios Mavroudis, Aysim Büge Öz, Bonne Biesma, et al.. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer, 2020, 147, pp.237-243. ⟨10.1016/j.lungcan.2020.07.026⟩. ⟨hal-03049824⟩